Source: European Journal of Clinical Pharmacology. Unidades: FMRP, EERP, FCFRP
Subjects: MEDICAMENTO, POLIMORFISMO, ÓXIDO NÍTRICO, ANESTESIA, PRESSÃO SANGUÍNEA
ABNT
OLIVEIRA-PAULA, Gustavo Henrique et al. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability. European Journal of Clinical Pharmacology, v. 77, n. 6, p. 869-877, 2021Tradução . . Disponível em: https://doi.org/10.1007/s00228-020-03059-9. Acesso em: 20 ago. 2024.APA
Oliveira-Paula, G. H., Coeli-Lacchini, F. B., Ferezin, L. P., Ferreira, G. C., Pinheiro, L. C., Garcia, W. N. de P., et al. (2021). Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability. European Journal of Clinical Pharmacology, 77( 6), 869-877. doi:10.1007/s00228-020-03059-9NLM
Oliveira-Paula GH, Coeli-Lacchini FB, Ferezin LP, Ferreira GC, Pinheiro LC, Garcia WN de P, Garcia LV, Tanus-Santos JE, Lacchini R. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability [Internet]. European Journal of Clinical Pharmacology. 2021 ; 77( 6): 869-877.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1007/s00228-020-03059-9Vancouver
Oliveira-Paula GH, Coeli-Lacchini FB, Ferezin LP, Ferreira GC, Pinheiro LC, Garcia WN de P, Garcia LV, Tanus-Santos JE, Lacchini R. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability [Internet]. European Journal of Clinical Pharmacology. 2021 ; 77( 6): 869-877.[citado 2024 ago. 20 ] Available from: https://doi.org/10.1007/s00228-020-03059-9